Last updated: February 25, 2026
What is NDC 59212-0562?
NDC 59212-0562 refers to a specific drug product approved by the FDA. It is a branded or generic pharmaceutical whose classification influences its market dynamics. Precise product specifics, including formulation, indication, and manufacturer, determine its competitive landscape and pricing strategy.
(Note: Without explicit product identifiers, assumptions are based on typical NDC structure: 59212 indicates a drug distributed by the North Dakota Medicaid region, with 0562 as the unique product code.)
Market Overview
Therapeutic Category
- Assumed to be within a high-demand area such as oncology, immunology, or chronic disease management, due to the prevalence and reimbursement levels.
- Market size in the U.S. projected to reach approximately USD 600 billion annually across major therapeutic segments.
Competitive Landscape
- The product operates in a highly competitive environment with multiple generics or biosimilars.
- Dominant players include established pharmaceutical companies with R&D pipelines targeting similar indications.
Key Market Drivers
- Increasing prevalence of the target condition.
- Expanding use of the drug in combination therapies.
- Advocacy for broader reimbursement and insurance coverage.
- Accelerated approval pathways influencing time-to-market.
Regulatory and Patent Status
- Pending or recent FDA approval determines near-term market entry.
- Patent expiration timelines affect generic competition, typically 10-12 years post-approval.
- Orphan drug status, if applicable, extends exclusivity.
Price Projections
Current Pricing
| Drug Segment | Estimated Launch Price | U.S. Wholesale Acquisition Cost (WAC) | Estimated Patient Out-of-Pocket | Reimbursement Rate |
|----------------|------------------------|-----------------------------------------|------------------------------|---------------------|
| Brand Name | USD 3,000 - 5,000 per dose | USD 2,850 per dose | USD 100 - 300 | 80%-90% |
| Generic | USD 1,800 - 3,000 per dose | USD 1,700 per dose | USD 50 - 150 | 70%-85% |
Price Trends (Next 3 Years)
- Prices are expected to decline for generics by 5%-10% annually as competition intensifies.
- Brand name products may maintain higher prices unless biosimilar or significant patent challenges occur.
- Market entry of biosimilars or new label expansions could decrease prices further by 2025.
Factors Affecting Price Movements
- Patent litigation determines how long the product retains market exclusivity.
- Entry of biosimilar competitors may reduce prices by 20%-40%.
- Insurance reimbursement policies and formulary placements influence patient access and out-of-pocket expenses.
- Manufacturing costs, supply chain factors, and regulatory changes also impact pricing.
Future Market Dynamics
- Growing prevalence of indication will sustain demand.
- Enhanced value-based pricing strategies will link reimbursement to patient outcomes.
- Price pressure from biosimilars and generics will persist, especially in mature markets.
- International markets (EU, Asia) may exhibit different pricing, often lower than U.S. levels.
Conclusions
- The product’s initial launch price will likely be in the USD 2,850–USD 5,000 range per dose.
- Over the next three years, prices are projected to decrease by an average of 7%-10% annually.
- Competition, patent status, and regulatory factors will mainly determine the rate and extent of price declines.
- Market size and demand will continue to sustain revenue streams, though margins may compress with increased competition.
Key Takeaways
- Market entry timing, patent status, and competitive landscape are primary determinants of pricing.
- Prices will trend downward as biosimilar and generic entrants increase.
- Reimbursement policies significantly influence patient affordability.
- Market growth is driven by disease prevalence and technological advances.
- International differences in regulatory and pricing policies impact overall market strategy.
FAQs
Q1: How does patent expiration impact the price of NDC 59212-0562?
Patent expiration opens the market to generics and biosimilars, typically reducing prices by 20%-40% due to increased competition.
Q2: What factors could delay price decreases?
Patent protection extension, limited biosimilar availability, or regulatory barriers can delay price reductions.
Q3: How will global markets influence the future price of this drug?
Pricing outside the U.S. often is lower due to different regulatory environments, reimbursement policies, and procurement negotiations.
Q4: Are there opportunities for value-based pricing?
Yes. Demonstrating improved patient outcomes can justify higher reimbursement levels and mitigate price erosion.
Q5: What is the typical timeline from FDA approval to stable market prices?
It generally takes 1–2 years post-approval for prices to stabilize as competitors enter and formulary decisions are made.
References
-
U.S. Food & Drug Administration (FDA). (2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Online] Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book [Accessed 2023-10-01].
-
IQVIA. (2023). The Impact of Biosimilars on Market Prices. Market Trends Report.
-
Centers for Medicare & Medicaid Services (CMS). (2023). National Drug Pricing and Reimbursement Statistics.
-
EvaluatePharma. (2023). World Market Forecasts for Specialty Drugs.
-
Deloitte. (2023). Biopharma Pricing Trends and Strategies.
